Sanofi-aventis CEO indicates progress made in talks with Genzyme

Sanofi-aventis CEO Chris Viehbacher indicated Wednesday that the company has "made some progress" in its acquisition talks with Genzyme, adding that discussions over a contingent value right (CVR) remain the "priority item" between the parties. "There are still gaps," Viehbacher remarked, noting that whether a CVR linked to Lemtrada "is enough to entirely close the gap we will have to wait and see." The executive said "I think we would expect that given the forecasts, which we don't necessarily share, that it could be of significant value to Genzyme shareholders."

Reference Articles
Sanofi CEO says Genzyme progress made, still some differences - (Bloomberg)
Sanofi CEO sees progress in Genzyme talks - (FinanzNachrichten)

**Published in "First Word"